Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236197 · ClinicalTrials.gov registry record · Phase 3
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
A Phase 3 study of Heartburn, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 619
- Enrollment target
- 1
- Study location
NCT00236197 is a Phase 3 study of Heartburn that has completed, run by Eisai. The registered enrollment target is 619 participants, above the 351-participant average among 9 other Heartburn trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00236197, a Phase 3 study of Heartburn, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 619 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn.
Conditions Studied
Interventions
- DRUG placebo
- DRUG rabeprazole sodium
Study Locations (1)
New York
- New York Center For Clinical Research - Lake Success
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 619 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00236197
The ClinicalTrials.gov registry entry for NCT00236197 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 619 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 351-participant average among 9 other Heartburn trials with a reported enrollment target (76% higher). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heartburn appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00236197 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00236197 about?
NCT00236197 is a clinical study titled "E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers". The purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn.
What is the current status of trial NCT00236197?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 619 participants. The study started on 2005-10. Estimated completion is 2008-06.
What conditions does trial NCT00236197 study?
This clinical trial studies the following conditions: Heartburn.
What interventions are being tested in trial NCT00236197?
The interventions under investigation include: placebo (DRUG), rabeprazole sodium (DRUG).
Who is sponsoring clinical trial NCT00236197?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00236197 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heartburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.